Sort by
Refine Your Search
-
Category
-
Program
-
Employer
-
Field
-
engineering projects is increasingly complex, particularly when balancing human expertise and Large Language Models as collaborative agents. This project aims to propose a reputation-based agentic Artificial
-
– Refª C628696807-00454142 funded by Recovery and Resilience Plan (RRP) https://recuperarportugal.gov.pt/ and Next Generation EU European Funds Application submission from 13 to 26 February 2026 WHO WE
-
Socially-Aware AI agent to enhance team training by providing real-time insights and actionable feedback from multimodal data. We envision that humans and agents will work in teams, complementing each other
-
functionalities for autonomous driving, as well as an immersive, multi-agent urban simulation platform for validating autonomous driving algorithms, pedestrian–autonomous/manual vehicle interaction, and human
-
of the following activities: Activity 1: Assessment of the direct effects of the biological control agent Trichilogaster acaciaelongifoliae Assess the establishment of the biological control agent along
-
, cytocompatibility testing and evaluation of cellular response to therapeutic agents, as well as assisting with technical documentation and preparation of scientific publications, in the scope of the Élpis project
-
and fermented fractions; (ii) development and optimization of oleogel formulations using insect-derived oils combined with suitable structuring agents and antioxidants; (iii) evaluation of the stability
-
, Researcher María Zozaya Montes. (Center/Dep.) CIDEHUS of the University of Évora email: mzozayam@uevora.pt (in open copy to: cidehus@uevora.pt ) ANNEX I, ANNEX II, ANNEX III: https://www.uevora.pt
-
@uevora.pt (in open copy to: cidehus@uevora.pt ) ANNEX I, ANNEX II, ANNEX III: https://www.uevora.pt/investigar/Oportunidades-de-Investigacao/concursos-bolsas-id Where to apply E-mail mzozayam@uevora.pt
-
Instituto de Investigação e Inovação em Saúde da Universidade do Porto (i3S) | Portugal | 3 months ago
combination with immune checkpoint inhibitors, and determine the impact of combination therapy versus each agent alone on lymphoma growth. Since anthracycline chemotherapeutic drugs can induce immunogenic cell